Cytosorbents (CTSO) Q3 2024 earnings summary

Executive summary

• Q3 2024 product sales reached $8.6 million, up 11% year-over-year, with total revenue of $9.4 million, driven by international direct sales and distributor network strength.

• Net loss narrowed to $2.3 million ($0.04/share), a significant improvement from $9.2 million in Q3 2023, aided by cost controls and a $2.7 million gain on foreign currency transactions.

• DrugSorb-ATR regulatory submissions completed in the U.S. and Canada, with FDA De Novo application accepted for review in October 2024 and Health Canada review underway; decisions expected in 2025.

• CytoSorb generated $34 million in trailing 12-month sales, with over 250,000 devices used in 76 countries, and international business remains strong.

• Cash, cash equivalents, and restricted cash totaled $12.2 million at quarter-end, with concerns about funding operations beyond the next 12 months.

Financial highlights

• Q3 2024 revenue was $9.4 million (+7% YoY); product sales were $8.6 million (+11% YoY); grant income declined 26% YoY.

• Product gross margin was 61%, down from 72% in Q3 2023 due to planned production slowdown and manufacturing issues, with normalization expected in Q4 2024.

• Operating expenses decreased 25% YoY to $9.7 million, reducing operating loss by 40%.

• Adjusted EBITDA loss improved to $3.5 million from $5.6 million YoY; adjusted net loss improved to $4.5 million ($0.08/share) from $6 million ($0.14/share).

• Cash burn reduced to $2.7 million in Q3 2024 from $5.0 million in Q2 2024.

Outlook and guidance

• Expect return to normalized production levels and gross margins in Q4 2024, with long-term gross margin targets of 75%-80%.

• Regulatory decisions for DrugSorb-ATR in the U.S. and Canada anticipated in 2025, potentially enabling North American market entry.

• Management expects cost-cutting and milestone-driven cash releases to fund operations through 2025 if milestones are met; additional capital may be required if milestones are not achieved.

• Taiwan launch expected to accelerate in the next year following recent regulatory approval.

• Focus remains on margin expansion and achieving cash flow breakeven.